Core Viewpoint - Harmony Biosciences Holdings, Inc. will report its fourth quarter and full year 2025 financial results on February 24, 2026, before the U.S. financial markets open [1] Financial Reporting - The financial results will be discussed in a conference call and webcast scheduled for February 24, 2026, at 8:30 a.m. ET [1] - Participants can join the call by dialing 800-274-7083 for domestic calls or 203-518-9786 for international calls, using the passcode HRMYQ425 [1]

Core Viewpoint - Harmony Biosciences Holdings, Inc. (HRMY) is highlighted as a reasonably valued biopharma firm, with a focus on its stock performance since the last analysis in June of the previous year [1]. Group 1: Company Overview - Harmony Biosciences is positioned within the biotech sector, which is characterized by high beta and potential for significant investor returns [1]. - The company is part of a model portfolio that includes 12-20 high upside biotech stocks, indicating a strategic selection aimed at maximizing investment opportunities [1]. Group 2: Analyst Background - The analyst, Bret Jensen, has over 13 years of experience as a market analyst, specializing in identifying high-potential investments in the biotech sector [1]. - The Biotech Forum, led by the analyst, offers live discussions on trade ideas, market commentary, and weekly updates on portfolio performance [1].

Company Overview - Harmony Biosciences is a U.S.-based biopharmaceutical company focused on therapies for rare neurological diseases, with WAKIX being a notable product for narcolepsy [5] - The company reported a total revenue of $825.94 million and a net income of $185.68 million for the trailing twelve months (TTM) [4] - The company has 268 employees and experienced a 1-year price change of -5.92% as of January 31, 2026 [4] Recent Executive Transactions - Sandip Kapadia, the Chief Financial Officer, sold 3,746 shares on January 26, 2026, for approximately $139,171 [1][2] - Following this transaction, Kapadia's direct holdings decreased to 24,521 shares from over 127,000 shares in March 2023 [8] - The transaction value was based on a weighted average purchase price of $37.15, with a post-transaction value of $916,105 based on the market close of $37.36 [2] Financial Performance and Outlook - Harmony Biosciences expects to achieve over $1 billion in revenue from WAKIX by the end of 2026, supported by an exclusive license for the medication [9] - The company has other medications in advanced development stages, projected to sustain operations into 2040 [10] - A 10% revenue increase is anticipated for 2025, indicating strong financial results and a positive outlook for investors [10] Investor Implications - Despite the recent sale by Kapadia, Harmony Biosciences' financials remain strong, particularly highlighted by a robust Q3 2025 net income, the highest since Q3 2022 [7] - The recent sale size of 3,746 shares is significantly below Kapadia's median sale size of 13,494 shares, suggesting a potential for further material sales [8]

Core Insights - Harmony Biosciences has shown promising financial performance, but the CFO, Sandip Kapadia, sold all her direct equity ownership in January 2026, raising questions about insider sentiment [1][6]. Financial Overview - As of January 31, 2026, Harmony Biosciences' stock price was $35.52, with a market capitalization of $2.1 billion, revenue of $825.94 million, and net income of $185.68 million [4]. - The transaction involved the sale of 20,961 shares for approximately $752,800, executed at a weighted average price of $35.92 per share [2][9]. Company Profile - Harmony Biosciences is a U.S.-based biopharmaceutical company focused on therapies for rare neurological diseases, with WAKIX being a notable product for treating narcolepsy [5]. Future Outlook - The company anticipates over $1 billion in revenue from WAKIX by the end of 2026, supported by an exclusive license for the medication [7]. - Other medications in advanced development stages are projected to sustain revenue generation into 2040, with a 10% increase in 2025 [8]. Insider Trading Context - Kapadia's sale fully liquidated her direct holdings, which had previously been reduced from 72,948 shares to zero over the past year [9]. - The sale price was slightly below the market close of $36.41 on the transaction date and below the current share price of $36.62 as of January 31, 2026 [9].

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Harmony Biosciences Holdings, Inc. (HRMY) identified as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10]. Group 1: Earnings Growth - Harmony Biosciences has a historical EPS growth rate of 13.1%, but projected EPS growth for this year is significantly higher at 26.7%, surpassing the industry average of 13% [4]. - Double-digit earnings growth is a key indicator for growth investors, suggesting strong future prospects and potential stock price increases [3]. Group 2: Cash Flow Growth - The company currently exhibits a year-over-year cash flow growth of 10%, which is notably higher than the industry average of -4.5% [5]. - Over the past 3-5 years, Harmony Biosciences has achieved an annualized cash flow growth rate of 25.7%, compared to the industry average of 4.1% [6]. Group 3: Earnings Estimate Revisions - Recent upward revisions in current-year earnings estimates for Harmony Biosciences indicate a positive trend, with the Zacks Consensus Estimate increasing by 7.5% over the past month [8]. - The correlation between earnings estimate revisions and stock price movements supports the potential for near-term price appreciation [7]. Group 4: Overall Assessment - Harmony Biosciences has achieved a Zacks Rank of 1 (Strong Buy) and a Growth Score of B, indicating its potential as an outperformer and a solid choice for growth investors [10].

Core Insights - Investors in the Medical - Biomedical and Genetics sector should consider Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX) for potential value opportunities [1] Valuation Metrics - HRMY has a forward P/E ratio of 9.20, significantly lower than ARGX's forward P/E of 29.47 [5] - HRMY's PEG ratio is 0.34, while ARGX's PEG ratio is 0.54, indicating HRMY may offer better value relative to its expected earnings growth [5] - HRMY has a P/B ratio of 2.54 compared to ARGX's P/B of 8.18, further suggesting HRMY is undervalued [6] Zacks Rank and Earnings Outlook - HRMY holds a Zacks Rank of 1 (Strong Buy), indicating positive earnings estimate revisions, while ARGX has a Zacks Rank of 5 (Strong Sell) [3] - The stronger estimate revision activity for HRMY suggests a more favorable earnings outlook compared to ARGX [7] Value Grades - HRMY has a Value grade of A, while ARGX has a Value grade of D, reflecting HRMY's more attractive valuation metrics [6]

Core Viewpoint - Harmony Biosciences is entering 2026 with significant momentum driven by three key factors: strong performance of WAKIX, a robust late-stage pipeline, and a strong financial profile [3][4]. Group 1: WAKIX Performance - WAKIX has shown five years of consecutive growth and profitability, with guidance for 2026 indicating over $1 billion in net revenue, positioning it to achieve blockbuster status this year [3]. Group 2: Late-Stage Pipeline - The company has five Phase III programs in the clinic targeting five distinct CNS indications, which are expected to provide multiple catalysts in the coming years [4]. Group 3: Financial Profile - Harmony Biosciences is characterized by a strong financial profile, indicating profitability and a solid foundation for future growth [4].

Harmony Biosciences FY Conference Summary Company Overview - **Company**: Harmony Biosciences (NasdaqGM:HRMY) - **Event**: 44th JPM Healthcare Conference - **Date**: January 13, 2026 Key Industry Insights - **Core Focus**: Central Nervous System (CNS) disorders, particularly narcolepsy and related conditions - **Product Highlight**: WAKIX, a treatment for narcolepsy, is on track to achieve blockbuster status in 2026 with projected net revenue exceeding $1 billion Core Points and Arguments 1. **Momentum and Growth**: Harmony enters 2026 with significant momentum driven by three key factors: WAKIX performance, a robust late-stage pipeline, and a strong financial profile [2][3] 2. **WAKIX Performance**: WAKIX has shown five years of consecutive growth and profitability, with 2025 net revenue reported at $868 million, exceeding guidance [9][41] 3. **Pipeline Development**: Five phase three programs are advancing towards distinct CNS indications, setting up multiple catalysts for growth in the coming years [2][24] 4. **Pitolisant Franchise Expansion**: The introduction of Pitolisant GR (gastro-resistant formulation) and Pitolisant HD (high-dose formulation) aims to address unmet patient needs and expand the franchise [4][13] 5. **Market Opportunity**: There are approximately 80,000 diagnosed narcolepsy patients in the US, with an additional 90,000 undiagnosed, indicating significant growth potential for WAKIX [10][42] 6. **Commercial Strategy**: Harmony has improved its commercial operations, achieving broad formulary access (80% of lives covered) and enhancing patient support systems [11][27] 7. **Regulatory Milestones**: Anticipated NDA submission for Pitolisant GR in Q2 2026, with a PDUFA date expected in Q1 2027 [30][37] 8. **Financial Health**: Harmony maintains a strong balance sheet with over $770 million in cash, allowing for continued investment in pipeline development and business growth [44][45] Additional Important Insights - **Patient-Centric Approach**: The company emphasizes the importance of addressing patient needs, particularly in narcolepsy and related disorders, through innovative product formulations [4][14] - **Unique Product Profiles**: The differentiated profiles of Pitolisant formulations are expected to enhance clinical utility and market competitiveness [6][39] - **Future Catalysts**: Anticipated data readouts from ongoing trials in 2027 and 2028 for various CNS indications, including Prader-Willi syndrome and epilepsy programs [21][20] - **Business Development Focus**: Harmony is actively seeking strategic opportunities to expand its portfolio in the CNS space, particularly in orphan and rare diseases [44][45] This summary encapsulates the key points discussed during the conference, highlighting Harmony Biosciences' strategic direction, product pipeline, and market opportunities within the CNS industry.

Financial Performance and Growth - Harmony Biosciences anticipates net revenue between $1 billion and $1.04 billion for 2026[16] - The company's revenue has grown consistently year-over-year, with $714.7 million in 2024, $868 million in 2025, and projected growth into 2026[52] - WAKIX net revenue has shown significant growth from $160 million in 2020 to over $1 billion projected for 2026[15] Pitolisant Franchise Strategy - The company is focused on growing the WAKIX franchise, extending it with Pitolisant GR, and expanding it with Pitolisant HD[8] - Pitolisant GR has the potential to extend the pitolisant franchise with utility patents filed to 2044[9] - Pitolisant HD has the potential to expand the pitolisant patient base into new indications[9] Pipeline Development - A Phase 1 clinical PK data for BP1.15205, a potential best-in-class Orexin 2 Receptor (OX2R) Agonist, is anticipated in mid-2026[42] - Topline data from ongoing global Phase 3 trials for EPX-100 in Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) are anticipated in 1H 2027[45, 47] - The company submitted an NDA for Pitolisant GR in Q2 2026, with an anticipated PDUFA date in Q1 2027[31] Market Opportunity - There are approximately 170,000 people living with narcolepsy in the U S, with over 50% undiagnosed[22]

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Harmony Biosciences Holdings, Inc. (HRMY) being highlighted as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10]. Group 1: Earnings Growth - Harmony Biosciences has a historical EPS growth rate of 13.1%, with projected EPS growth of 19.6% for the current year, significantly outperforming the industry average of 12.2% [5]. Group 2: Cash Flow Growth - The company exhibits a year-over-year cash flow growth of 10%, which is notably higher than the industry average of -3.8% [6]. - Over the past 3-5 years, Harmony Biosciences has maintained an annualized cash flow growth rate of 25.7%, compared to the industry average of 4.1% [7]. Group 3: Earnings Estimate Revisions - The current-year earnings estimates for Harmony Biosciences have been revised upward, with the Zacks Consensus Estimate increasing by 0.1% over the past month [9]. Group 4: Overall Positioning - Harmony Biosciences has achieved a Growth Score of A and holds a Zacks Rank 2, indicating strong potential for outperformance in the growth stock category [10][11].